Market Access

With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, In Vivo looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.

Compassionate use programs (CUP) are a developing field in Asian countries. In the majority of Asian states, the CU applies to Named-Patients Program (NPP). In the most countries, understanding of CUP for unapproved drugs is poor among the public, and even for professional communities. 

Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action. 

An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.

Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.

Mark Cuban’s newly launched online pharmacy and pharmacy benefit manager operation in the US has sparked interest in India. Can the billionaire entrepreneur’s venture punch above its weight and should Indian firms be watchful?

The formulas for various COVID-19 vaccines remain shrouded in intellectual property protections – one of many factors preventing them from being manufactured in developing nations. Those in favor of upholding IP say that scrapping patents could stifle future innovation, but their opponents believe preserving COVID-19 related IP rights is limiting access to lifesaving medical tools.

As a growing strategic priority across the health care industry, real-world evidence is increasingly being recognized for its potential to transform patient care.

Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.

Exploring the continued controversy around the 340B US federal drug discount program. As the story moves into 2022, key questions remain unanswered.

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

While US biosimilar approvals have been thin on the ground in 2021 – with products delayed due to the FDA’s inability to conduct certain facility inspections during the COVID-19 pandemic – the market has nevertheless seen several firsts this year, including two interchangeability designations and the first ophthalmic biosimilar approval.